EA202192257A1 - SILICON AND MAGNESIUM COMBINATION FOR PREVENTION AND TREATMENT OF MUSCLE CONTRUSIONS - Google Patents

SILICON AND MAGNESIUM COMBINATION FOR PREVENTION AND TREATMENT OF MUSCLE CONTRUSIONS

Info

Publication number
EA202192257A1
EA202192257A1 EA202192257A EA202192257A EA202192257A1 EA 202192257 A1 EA202192257 A1 EA 202192257A1 EA 202192257 A EA202192257 A EA 202192257A EA 202192257 A EA202192257 A EA 202192257A EA 202192257 A1 EA202192257 A1 EA 202192257A1
Authority
EA
Eurasian Patent Office
Prior art keywords
silicon
contrusions
muscle
prevention
treatment
Prior art date
Application number
EA202192257A
Other languages
Russian (ru)
Inventor
Баудевейн Луис Рене Андре Колсат
Кристианне Аугуста Адольф Ван Ворен
Original Assignee
Био Минералз Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Био Минералз Нв filed Critical Био Минералз Нв
Publication of EA202192257A1 publication Critical patent/EA202192257A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Фармацевтическая композиция, содержащая фармацевтически эффективное количество биодоступного кремния в суточной дозе по меньшей мере 3 мг элементарного кремния и фармацевтически эффективное количество соединения магния в суточной дозе 50-500 мг элементарного магния. Композицию применяют для предупреждения, ингибирования и/или лечения мышечных судорог, таких как судороги скелетных мышц.A pharmaceutical composition containing a pharmaceutically effective amount of bioavailable silicon in a daily dose of at least 3 mg of elemental silicon and a pharmaceutically effective amount of a magnesium compound in a daily dose of 50-500 mg of elemental magnesium. The composition is used to prevent, inhibit and / or treat muscle cramps such as skeletal muscle cramps.

EA202192257A 2019-02-15 2020-02-14 SILICON AND MAGNESIUM COMBINATION FOR PREVENTION AND TREATMENT OF MUSCLE CONTRUSIONS EA202192257A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157526.5A EP3695843A1 (en) 2019-02-15 2019-02-15 Medicament for the prevention and treatment of muscle cramps
PCT/EP2020/053912 WO2020165415A1 (en) 2019-02-15 2020-02-14 Combination of silicon and magnesium for the prevention and treatment of muscle cramps

Publications (1)

Publication Number Publication Date
EA202192257A1 true EA202192257A1 (en) 2021-11-01

Family

ID=65443783

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192257A EA202192257A1 (en) 2019-02-15 2020-02-14 SILICON AND MAGNESIUM COMBINATION FOR PREVENTION AND TREATMENT OF MUSCLE CONTRUSIONS

Country Status (11)

Country Link
US (1) US20220143078A1 (en)
EP (2) EP3695843A1 (en)
JP (1) JP2022520962A (en)
KR (1) KR20220004956A (en)
CN (1) CN113853202A (en)
AU (1) AU2020223517A1 (en)
BR (1) BR112021015682A2 (en)
CA (1) CA3129115A1 (en)
EA (1) EA202192257A1 (en)
IL (1) IL285491A (en)
WO (1) WO2020165415A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200009089A1 (en) 2022-05-04 2023-11-04 Geofarma S R L COMPOSITION BASED ON BIOAVAILABLE SILICON AND VITAMINS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922765A (en) * 1996-01-18 1999-07-13 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength
US20050196434A1 (en) * 2004-03-04 2005-09-08 Brierre Barbara T. Pharmaceutical composition and method for the transdermal delivery of magnesium
US20050220865A1 (en) * 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
EP3307083A4 (en) * 2015-06-11 2019-05-22 Beachbody, LLC Compositions and methods to improve exercise performance and recovery

Also Published As

Publication number Publication date
CN113853202A (en) 2021-12-28
JP2022520962A (en) 2022-04-04
EP3695843A1 (en) 2020-08-19
BR112021015682A2 (en) 2021-10-26
KR20220004956A (en) 2022-01-12
US20220143078A1 (en) 2022-05-12
IL285491A (en) 2021-09-30
WO2020165415A1 (en) 2020-08-20
EP3923955A1 (en) 2021-12-22
CA3129115A1 (en) 2020-08-20
AU2020223517A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CR20210563A (en) Compounds and methods for the treatment of covid-19
MA40111B1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
RU2015107877A (en) METHODS FOR TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS
HUP0101268A2 (en) Pharmaceutical compositions for treating female sexual dysfunction
TW200639159A (en) Treatment of pain
BR9908030A (en) Pharmaceutical composition comprising one or more orally administered dose units, and processes for preparing it, for use thereof, and for treating a medical condition or disorder in an individual in whom treatment with a cyclooxygenase-2 inhibitor is indicated
TW200806299A (en) Treatment of pain
CL2020000860A1 (en) Chroman monobactam compounds for the treatment of bacterial infections.
RU2017116740A (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
MX2021006156A (en) Compounds useful in hiv therapy.
NZ745065A (en) Methods for treatment and prophylaxis of hiv and aids
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
EA201990249A1 (en) APPLICATION AND DOSAGE MODE OF THERAPEUTIC AGENTS IN ENDOMETRIOSIS
RU2017120184A (en) DRUGS TO DELAY THE COURSE OF PARKINSON'S DISEASE
EA202192257A1 (en) SILICON AND MAGNESIUM COMBINATION FOR PREVENTION AND TREATMENT OF MUSCLE CONTRUSIONS
PH12020500666A1 (en) Pladienolide compounds and their use
MA39447A1 (en) (s) -pirlindole or its pharmaceutically acceptable salts for use in medicine
HUP0301828A2 (en) Use of apomorphine for the production of pharmaceutical compositions for treating sexual dysfunction with apomorphine at specified plasma concentration levels
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2019011558A (en) Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors.
PH12020551620A1 (en) Compositions for preventing or treating dry eye
EA202193050A1 (en) PHARMACEUTICAL COMBINATION INCLUDING TRAZODONE FOR THE TREATMENT OF NEUROPATIC PAIN
RU2020101999A (en) LIKOFLIGOSIN FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2022229441A3 (en) A specific combination of lipids and methods and uses related thereto